Member Info for Billions

Net revenue is a strange term tbh.

Japan is full of conglomerates could be anyone. Could be for financing or post likely forward sales and off take agreements.

"The Board appointed UBS as its leading financial adviser to assist in a review of its strategic options"

Sale is not and never has been the only option. Too many only post one side of the story or selected baised info.

Kopfkissin I read these as two separate options. Rights issue would be priced at the time and this gives the permission.

250k is separate to above.

No rights issue.

This is not sounding like a normal placing. Most likely the new shares will go straight to the "strategic" investor.

Full sale is looking increasingly unlikely from the tone of the whole rns. Imo not a bad thing long term.

Broxburn. Correct upto approx 10% new shares. Around 70m at current price. Calculation in another thread..

This could be a private placement, with the new shares allocated to any jv.

Sale, jv or other options. Looking like a jv is the way it's going. Which tbh would be best value for shareholders in the long term.

Calculation for the skeptics.

250k new allotment device by:
Current nominal value of shares from companies house: 2,693,756.753.

=9.28%

X 755m ncap

= 71m.

Yes Davere. Come to the same number. Can anyone confirm if this is correct? 9.28% dilution.

So up to 70m fund raise at current price.

Crusty...Posting lies does not make them true. Check pg 72 of the 2016 annual financial statements. Profit adjusted for non cash items was almost exactly 100m.

Another ranting and raving sheep.

Calm down lad, you are making a fool of yourself on a public forum.

Some advice, if you haven't got anything credible to add, next time just keep quite.

Don't really want to get into arguments. But most of the points you have raised are easily rebutted and still make the deal look cheap.

No answer as usual. It's good to see the the flip side for a change.

There is a massive difference between profitable proven assets and a development resource. Eua is somewhere in between.

No doubt it will be ignored again. Mac can you explain how 2moz JORC reserve was purchased by red emperor for 17.5m recently and how that figures into your "expert" views.

What you fail to note is the quoted deals were for producing miners generating 100m's profit for many years.

Still up a creek without a paddle. What would be more useful is if you can tell us how much Rh was produced by EUA to date or how much the Rh reserve is?

Spotify. Do your own research especially outside this BB. Compare to peers such as JLP, THST, SLP, SGL.

Looks at the report from ACF.

Look at recent russian deals such as KAZ, TSG, HGM. Also looks at recent FSP completions and ongoing ones.

After this roll the dice.

Indeed. In the interest of transparency, the Allergan deal was at around 5x the closing sp. The remaining was contingent on various milestones and deliverables.

It should be borne in mind that 100% premiums are rare, any higher premiums are usually for pharmaceutical and biotech.

Zippy for sure, this protracted process has had a notable impact on the logic, reasoning and basic decency of some posters here.

I'm afraid to contemplate what will happen to some if their predictions don't come true. For that reason taking a view that it's worth the share price and any premium however small is a bonus is the best option.

65p is as good as ANY guess here. It's at a realistic level and inline with the only professional report available from ACF.

I mean that's the point, it's the russian state, and maybe unfairly there is risk and trust issues. Would probably have been a different reaction if it was Oz or Canadian govt jv.

The value here is highly dependent on the next few months, deal would be instant gain, depending on the structure. Mining would probably be a bigger gain but more riskier and longer term.

New investors need to weigh this up

Thanks casa you are a great judge of character :) ... even though a loaded qu I'll share my view.

I said the rosgeo rns could potentially be game changing but too many questions for the market to fully value it. This will rerate on further news like cost, resource classification, exercise etc.

But ni denying it is positive, how much we dont know.